Expert guidance for treating BRAFV600E metastatic CRC

  • Jin Z & al.
  • Expert Rev Anticancer Ther
  • 27 Aug 2019

  • curated by Jim Kling
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • A review and expert opinion offers guidance on treating microsatellite instability-H (MSI-H)/deficient DNA mismatch repair (dMMR) tumors, treatment intensification, and combination treatment for metastatic colorectal cancer (mCRC).

Why this matters

  • There has been significant progress recently in improving response rates in BRAFV600E mCRC, which responds poorly to standard chemotherapy.

Key points

  • All patients with mCRC should be tested with a tumor mutation panel that includes RAS and BRAF.
  • MSI-H or MSI-H/dMMR tumors, regardless of BRAFV600E status, should be treated with immunotherapy, which has been shown to result in high and durable response.
  • Patients with BRAFV600E mCRC and favorable performance status can be considered for intensified treatment with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, folinate) + bevacizumab.
  • A 3-pronged approach, consisting of an epidermal growth factor receptor (EGFR) inhibitor, BRAF inhibitor, and MEK inhibitor, is effective in patients with BRAFV600E mCRC.
  • The optimal treatment strategy to avoid acquired drug resistance has not yet been determined.

Limitations

  • Expert opinion.